Concord Biotech Share Price

Concord Biotech Limited, with its corporate operations in Ahmedabad, functions as a biopharmaceutical company in India. The company develops and manufactures fermentation-based active pharmaceutical ingredients and high-quality formulations. Concord Biotech has a substantial reach with products sold in more than seventy countries across the globe. The company also has a presence in international markets through its subsidiaries in the USA and Japan .

Concord Biotech share price on NSE and BSE signifies how market participants react to the company’s operational performance and the overall developments in the biopharmaceutical sector. The company’s financial health depends on factors like API sales volumes, regulatory approvals from bodies like the USFDA, demand from international markets, and the performance of its formulations segment. Concord Biotech stock price gets influenced by various factors such as earnings reports, changes in global generic drug pricing, and trends in fermentation-based technology. In the longer run, strategies like new product development, capacity expansion, and contract development and manufacturing services affect the stock market sentiments. All these factors need monitoring to have an idea about the company’s stock price movements.

Concord Biotech share price provides real-time information about the last price traded, bid and ask prices, and volume traded. These indicators represent market activity and liquidity, reflecting investor response to corporate announcements, economic conditions, and sector news. Constant monitoring of the Concord Biotech stock price movements helps in observing short term price volatility and shows how a stock moves relative to the broader pharmaceutical index. Furthermore, monitoring Concord Biotech live price helps investors understand real-time market sentiment, price fluctuations, and trading behaviour. It allows them to evaluate short-term performance and respond to news, quarterly results, or sector trends that may influence the company’s valuation.

Concord Biotech Fundamentals 

A. Company Background

Concord Biotech Limited was incorporated in the year 2000 by Sudhir Vaid as a research‑driven biopharmaceutical company headquartered in Ahmedabad, Gujarat, India. The company specializes in the research, development and commercial manufacture of fermentation‑based Active Pharmaceutical Ingredients (APIs) and high‑quality finished formulations used by pharmaceutical companies globally. Over the past two decades, Concord has expanded from a niche single‑product API manufacturer into a broader producer of complex APIs and finished dosage forms, serving regulated and emerging markets worldwide. Concord’s manufacturing infrastructure includes multiple state‑of‑the‑art facilities near Ahmedabad that operate in compliance with international regulatory standards, enabling the company to supply products across diversified therapeutic segments and support contract research and manufacturing partnerships with global pharmaceutical firms.

B. Company Product Lines

• Active Pharmaceutical Ingredients (APIs)
  • Fermentation‑based and semi‑synthetic APIs for global pharmaceutical supply.

• Therapeutic segments include:
  • Immunosuppressants (e.g., tacrolimus, sirolimus, mycophenolate mofetil, cyclosporine)

• • Oncology (e.g., temsirolimus, everolimus, romidepsin)

• • Antibacterial agents (e.g., mupirocin, vancomycin, teicoplanin)

• • Antifungals (e.g., anidulafungin, micafungin, amphotericin B)

• • Other APIs (e.g., lovastatin, pravastatin)

• Finished Formulations
  • Solid oral dosage forms, liquids and suspensions manufactured under global quality standards.

• • Products covering therapeutic areas that complement the API portfolio and address critical care, nephrology and anti‑infective needs.

• Contract Research & Manufacturing Services (CRAMS)
  • Fermentation technology transfer, strain improvement, media optimization, process development and scale‑up.

• • Formulation development and manufacturing support for pharmaceutical partners’ product pipelines.

C. Company Revenue Model

• API Exports: Primary revenue from supplying complex APIs to global pharmaceutical companies, including regulated markets such as the United States and Europe.

• Finished Formulations: Revenue from sales of finished pharmaceutical dosage forms in international and domestic markets.

• CRAMS: Income from technical partnerships, custom manufacturing and research services provided to global pharmaceutical firms.

The business is centered on B2B pharmaceutical manufacturing and supply rather than retail consumer branding.

D. Geographic Presence

• Headquarters / Registered Office:
  • Ahmedabad, Gujarat, India

• Domestic Locations (Manufacturing & R&D):
  • Dholka, Gujarat: API manufacturing and R&D.

• • Valthera, Gujarat: Formulation manufacturing and R&D.

• • Limbasi, Gujarat: Second API manufacturing facility.

• International Presence:
  • Concord serves customers in 70+ countries across North America, Europe, Japan, Latin America, Africa and Asia‑Pacific markets through its global distribution network.
    (Note: Concord’s website and reports list presence through partnerships and distribution, not necessarily direct corporate offices in all these countries.)

E. Key Milestones

• 2000: Company founded by Sudhir Vaid; first API manufacturing facility (Dholka) established.

• 2000s: Dholka facility underwent multiple international regulatory inspections (USFDA, EU GMP, PMDA).

• 2011–2015: Valthera formulation facility established; R&D recognition by the Government of India; ANDA approvals for regulated markets.

• 2016–2020: Commissioning of Limbasi API facility; successful international regulatory inspections; entry into critical care and nephrology formulations.

• 2023: Company publicly listed on NSE and BSE.

• 2021–2024: Strategic equity investment in Palvella Therapeutics, renewable energy initiatives, and expansion of formulation capabilities, including injectable lines.

F. Industry Perspective

• The global API and biopharmaceutical manufacturing industry is growing due to rising demand for complex therapeutic molecules, regulatory compliance requirements and diversification of supply chains. India, as a key manufacturing hub, benefits from government initiatives (e.g., PLI schemes for fermentation‑based APIs) and its scientific talent base.

• Specialized manufacturers like Concord are positioned to serve high‑value segments, with fermentation‑based solutions increasingly preferred for complex APIs

Concord Biotech Stock Market Presence: Listings & Index Representation

Concord Biotech Limited is listed on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE). Concord Biotech share price is available for trading on the NSE under the symbol CONCORDBIO and on the BSE with the scrip code 543960 . The company’s market presence is primarily within the small-cap to mid-cap segment of the market. Due to its size and sector focus, Concord Biotech stock price is generally tracked by investors interested in the biopharmaceutical and fermentation-based API industry.

Concord Biotech is part of several broad-based and sector-specific stock market indices, reflecting its position as a small-cap biopharmaceutical company in India. Concord Biotech share price is a constituent of wider market indices such as the Nifty 500, which tracks a large universe of listed companies across sectors. The company is also included in the Nifty Smallcap 100 and BSE Healthcare indices . In addition, the company is included in multiple BSE indices, including the BSE 500 and broader composite indices like the BSE All Cap, which capture companies across large, mid, and small-cap segments.

Concord Biotech Stock Performance and Concord Biotech Share Price History

Concord Biotech share price on NSE reflects its status as a biopharmaceutical company focused on fermentation-based APIs and formulations in India. Performance gets driven by factors like API sales growth, regulatory approval success, export demand, and the company’s ability to manage operational costs effectively. Investors compare Concord Biotech share price today with other biopharmaceutical companies to gauge relative performance within the sector.

These underlying factors often appear through real market movements across different periods. Broader sector strength has played a role in supporting Concord Biotech share price. In addition to operational and sector-led factors, corporate actions such as dividend announcements can also have a significant impact on Concord Biotech share price movements in the short term. The company has regularly paid dividends to shareholders, showing its ability to reward them . This shows how corporate actions can trigger short-term swings, even within a regulated biopharmaceutical framework influenced by drug pricing policies and international regulatory standards.

While short-term movements reflect events and announcements, longer-term valuation trends become visible through Concord Biotech share price 52-week high and low, providing context beyond daily or weekly changes. Highs indicate strong product demand and stable margins, while lows align with market corrections or sector volatility. These levels capture the impacts of regulatory policies, competitive intensity, and earnings visibility, providing context for the stock’s historical performance.

Concord Biotech stock performance reflects the trading behaviour of a small-cap biopharmaceutical company operating within India’s regulated drug manufacturing system. The company’s diversified product portfolio across immunosuppressants, oncology, and anti-infectives has shaped its Concord Biotech share price history. Over time, the stock has shown long-term wealth creation, marked by periods of gains and phases of consolidation. The company successfully commissioned an injectable facility at Valthera, expanding its product portfolio into sterile injectables .

Concord Biotech stock performance over time has closely followed India’s pharmaceutical demand and global generic drug cycles. For instance, the company’s focus on fermentation-based niche products and its contract development and manufacturing services have been viewed favourably. Over longer investment horizons, the stock has delivered movements that highlight business expansion aligned with increasing demand for specialty biopharmaceuticals. However, the stock has also seen periods of underperformance due to dependency on certain key products and regulatory outcomes .

Despite the disruptions caused by the COVID-19 pandemic, Concord Biotech shares showed resilience. While the broader economy faced challenges with supply chains and logistics, the company’s focus on essential medicines and its vertically integrated manufacturing model helped the stock retain value. Prudent management and a strong reputation across its product portfolio kept shares stable amid the pandemic’s challenges and market volatility. The company’s manufacturing facilities continued to operate as part of essential services during lockdowns.

Concord Biotech share price has seen decreases due to several recurring reasons. A decline in API export sales or a drop in prices of key products in regulated markets like the USA directly impacts profitability and leads to selling pressure. Changes in government policy, such as price controls on drugs in India or changes in import regulations in key markets, can also cause the stock to fall. Furthermore, any increase in operational costs like raw material procurement costs or research expenses without a matching rise in product revenues squeezes the company’s margins, making the stock less attractive. Periods of economic slowdown that reduce healthcare spending raise concerns about revenue growth, leading to a drop in Concord Biotech share price. The stock is also sensitive to regulatory actions from the USFDA; if the agency issues observations or warning letters, it can lead to a decrease in Concord Biotech stock price as investors adjust expectations for future profitability . Broader market sell-offs in small-cap stocks also pull the price down, regardless of the company’s individual performance. A decrease in domestic formulation sales or lower demand from international customers directly hurts the company’s revenue, resulting in a lower valuation for Concord Biotech share price.

Concord Biotech Investor Relevance and Role in Portfolio

Concord Biotech is a holding in pharmaceutical and small-cap portfolios, offering exposure to fermentation-based APIs, formulations, and contract development and manufacturing services. Inclusion in healthcare indices underscores its importance in India’s specialty biopharmaceutical manufacturing space. The company’s diversified business model, strong presence in immunosuppressants, and growing international footprint make it a consideration for long-term allocations.

Concord Biotech equity is held by a broad mix of domestic and international institutional investors, reflecting its standing in India’s biopharmaceutical sector. Promoter holding remains stable at around forty four percent . Prominent mutual fund holders include Tata Mutual Fund and other domestic asset managers . Other institutional investors include Government Pension Fund Global and various foreign portfolio investors . This broad investor base with institutional participation underscores the company’s role as a holding in both domestic and global portfolios focused on biopharmaceutical manufacturing.

Beyond fundamentals and ownership, Concord Biotech share price is actively monitored in derivatives markets. The stock is available for trading in the futures and options segment on the NSE, allowing investors to take positions based on their outlook for the pharmaceutical sector. Market participants watch derivative indicators such as open interest and rollover patterns to gauge sentiment around quarterly results and policy announcements.

Technical indicators such as RSI, MACD, and MFI provide additional insight into short-term momentum shifts in the company’s stock price. While these indicators are primarily used for near-term trading decisions, they also help investors and portfolio managers understand broader market sentiment and anticipate potential volatility, especially around key events or announcements.

Concord Biotech stock price has exhibited certain volatility patterns. Concord Biotech beta has generally remained at levels reflecting its position as a small-cap biopharmaceutical stock with institutional participation and business fundamentals tied to the generic drug cycle. Over shorter timeframes, the stock has shown relatively higher sensitivity to market movements, indicating short-term volatility. During the three-month period, this sensitivity appears more balanced, suggesting a closer alignment with broader market trends. Across longer durations, the beta trends in a manner indicating reduced volatility and a weaker correlation with overall market fluctuations. This behaviour is typical for companies in the specialty biopharmaceutical sector with dependence on niche fermentation products. Overall, these variations across different timeframes highlight that while Concord Biotech may experience short-term fluctuations, its longer-term volatility remains characteristic of a small-cap pharmaceutical stock.

Concord Biotech Sectoral Relevance and Peer Positioning

Concord Biotech sector relevance stems from its scale in fermentation-based API manufacturing and its growing presence in contract development and manufacturing services. Peer comparisons with companies like Sun Pharma, Biocon, Divi’s Laboratories, Cipla, Torrent Pharma, and Dr. Reddy’s Laboratories focus on product differentiation, research capabilities, and geographical presence rather than short-term stock moves . These benchmarks help investors assess operational scale, efficiency, and regulatory adherence. Institutional tracking of USFDA approvals, generic drug pricing, and competitive intensity further highlights Concord Biotech positioning within India’s broader biopharmaceutical manufacturing market.

Concord Biotech market cap history shows the company’s position within the biopharmaceutical sector. Earlier in its history, the market capitalization remained at more moderate levels as the company operated primarily as an API manufacturer. The shift toward complex fermentation-based formulations and the commissioning of the injectable facility led to a re-evaluation by the market. This transition from a pure API supplier to a vertically integrated biopharmaceutical company has been a key factor in how the company’s overall valuation has evolved over time.

Concord Biotech earnings history demonstrates the impact of its strategic business decisions. In earlier periods, earnings reflected the cyclical nature of the generic drug business with exposure to competition and price erosion. As the company expanded its portfolio of niche fermentation products, earnings patterns showed periods of strong growth followed by normalization. The company’s focus on complex generics and its strategic investments contributed to changes in its earnings profile over the years. More recently, earnings have been supported by a strong performance in the API segment .

Concord Biotech EPS provides insight into its operational performance and income generation from APIs, formulations, and contract manufacturing services. Over the years, earnings per share have shown variation in line with the company’s business cycle and industry conditions. The shift toward higher-margin specialty products and the expansion of international markets have influenced the EPS trajectory. Quarterly performance reflects the ongoing earnings from both domestic and international operations, with regulated markets like the USA contributing to the overall per-share earnings picture .

Concord Biotech P/E ratio reflects how investors perceive the company’s earnings relative to its business model. In earlier years, the ratio remained at certain levels, indicating market expectations based on the company’s product pipeline and approval timelines. As the company received approvals for niche products and expanded its product portfolio, the valuation saw changes. The ratio has moved in response to how investors view the company’s prospects in areas like complex generics and international expansion. These changes highlight how market sentiment has evolved alongside the company’s business transformation .

Summary

Concord Biotech Limited develops, manufactures, and markets fermentation-based APIs and formulations for global markets. Concord Biotech share price on the NSE and BSE reflects trading activity within the biopharmaceutical manufacturing industry. The company has a notable presence in both domestic and international markets. Concord Biotech stock price is influenced by regulatory approvals, generic drug pricing, export demand, and broader economic factors. The company’s focus on niche fermentation products and vertical integration remains a key aspect of its business profile.